[ Price : $8.95]
In its latest batch of Warning Letters, FDA cites Aarti Drugs, Agila Specialties, Fenwal, Homeolab, Insight Pharmaceuticals, Medic...[ Price : $8.95]
The Institute of Medicine publishes a report on a two-day workshop on observational studies in clinical research.[ Price : $8.95]
Stakeholders recommend ways to best communicate REMS information to prescribers and patients.[ Price : $8.95]
FDAs San Juan District Office warns Fenwal about violations found in an inspection at a Puerto Rico drug and medical device manufa...[ Price : $8.95]
Stakeholders ask FDA to clarify how it will determine whether facility actions that delay or limit an agency inspection are unreas...[ Price : $8.95]
Horizon asks FDA to require specific data and information demonstrating bioequivalence of a generic version of its Rayos.[ Price : $8.95]
The U.S. Senate offers a temporary spending measure that could avert a government shut down, including a good portion of FDAs oper...[ Price : $8.95]
FDA releases a critical five-page, seven-observation FDA-483 from a January Dallas District Office inspection at BRI institutional...